Inhibition of dipeptidyl peptidase-4 (DPP-4) is currently explored as a novel therapy of type 2 diabetes. The strategy has been shown to improve glycemia in most, but not all, rodent forms of glucose intolerance. In this study, we explored the effects of DPP-4 inhibition in mice with β-cell overexpression of human islet amyloid polypeptide (IAPP). We therefore administered the orally active and highly selective DPP-4 inhibitor, vildagliptin (3µmol/mouse daily) to female mice with β-cell overexpression of human IAPP. Controls were given plain water, and a series of untreated wildtype mice was also included. After five weeks, an intravenous glucose tolerance test showed improved glucose disposal and a markedly enhanced insulin response in mice treated with vildagliptin. After eight weeks, a gastric tolerance test showed that vildagliptin improved glucose tolerance and markedly (approximately ten-fold) augmented the insulin response in association with augmented (approximately five-fold) levels of intact glucagon-like peptide-1 (GLP-1). Furthermore, after nine weeks, islets were isolated.
Introduction
Prevention of inactivation of glucagon-like peptide-1 (GLP-1) by inhibition of the enzyme dipeptidyl peptidase-4 (DPP-4) is a strategy that is currently being developed as a novel treatment for type 2 diabetes (1-3). DPP-4 inhibition has thereby been demonstrated to be anti-diabetic both in animal models of diabetes (4) (5) (6) (7) and in patients with type 2 diabetes (8) (9) (10) . The antidiabetic action of DPP-4 inhibition is explained by increased insulin secretion in association with inhibited glucagon secretion with a possible long-term action to increase β-cell mass (1) (2) (3) . Since the actions of DPP-4 inhibition thus rely on islet function, severely deranged islet function may compromise the antidiabetic action of this strategy. This was previously demonstrated in transgenic mice with ß-cell targeted dominantnegative mutant hepatocyte nuclear factor (HNF)-1α, a model of severe islet dysfunction underlying the genetic syndrome known as maturity-onset diabetes of the young (variant 3), and in which DPP-4 inhibition has weak and compromised effect (11) . In the present study, we explored the effects of DPP-4 inhibition in mice with a targeted β-cell overexpression of human islet amyloid polypeptide (hIAPP) (12, 13) . IAPP is produced in the β-cells and inhibits insulin secretion (14) (15) (16) . IAPP of the human form may form fibrils leading to islet amyloid deposition, β-cell dysfunction and type 2 diabetes (17, 18) . We have previously shown that mice with β -cell specific overexpression of hIAPP have severe glucose intolerance and defective insulin response to gastric glucose (12) . In the present study, we explored whether DPP-4 inhibition improves glucose tolerance and insulin secretion in these mice. Since we previously have reported that the islets in transgenic human IAPP mice show disturbed topography with glucagon cells within the central β-cell area (19) , we also explored the islet topography to examine whether DPP-4 inhibition could improve the β-cell topography in this model. Transgenic mice were treated over a nine-week period with the orally-active and highly selective DPP-4 inhibitor vildagliptin
previously labeled LAF237 (20) , added to the drinking water. Control mice were given plain water. Non-treated wildtype mice served as an additional control group.
Methods.

Animals.
Hemizygous transgenic mice with islet β-cell expression of hIAPP on a C57BL/6J/6xDBA/2 background were generated as previously described (21) . Transgenic status was determined by PCR using oligonucleotide primers directed against the hIAPP transgene (22). The transgenic mice and their wildtype controls were kind gifts of Dr Steven E Kahn, University of Washington, Seattle, WA. Transgenic and wildtype mice were transported from the animal facility of the University of Washington, Seattle, to the In Vivo Department, Biomedical Center, Lund University, Lund after embryo transfer performed at Taconic A/S, Ry, Denmark. The animals were cross-bred for >16 generations to C57BL/6J mice. The animals were kept in a 12 h light schedule (lights on at 0600 am) and given a standard pellet diet (fat 11.4%, carbohydrate 62.8%, protein 25.8% on an energy base, total energy 12.6 kJ/g) and tap water ad libitum. The Animal Ethics Committee, Lund and Malmö, approved the study.
Design of the study and in vivo experiments.
Female mice were used in this study. We previously showed no gender difference in glucose tolerance or insulin secretion after gastric or intravenous glucose in mice with β-cell overexpression of hIAPP (12) . When mice were 2 months of age, half of the mice were given the DPP-4 inhibitor, vildagliptin (a kind gift from Novartis Institutes for BioMedical Research, Cambridge, U.S.A.) in the drinking water (0.3mg/ml, ∼3µmol vildagliptin/day/mouse). Control mice were given tap water without vildagliptin and an additional series of untreated wildtype mice was also included. The mice were then followed for nine weeks with regular measurements of body weight. Intravenous glucose tolerance test was undertaken after five weeks and a gastric glucose tolerance test was undertaken after eight weeks. After nine weeks, islets were isolated for studies of glucose-stimulated insulin secretion in vitro, and pancreas was analyzed by immunocytochemistry for islet topography. 
Islet immunocytochemistry.
Pancreas was dissected and processed for immunocytochemistry according to previously published protocols (24) . Briefly, cryosections were incubated with primary antibodies: guinea pig polyclonal anti-proinsulin, code: 9003, dilution: 1:2560 (EuroDiagnostica, Malmö, Sweden) and rabbit polyclonal anti-glucagon, code: 7811, dilution:
1:5120 (EuroDiagnostica). Sections were rinsed and thereafter incubated with secondary antibodies with specificity for rabbit-or guinea pig-IgG, and coupled to either fluorescein isothiocyanate (FITC) or Texas-Red (Jackson, West Grove, PA, USA). Sections were again rinsed and then mounted. Immunofluorescence was examined in epifluorescence microscope (Olympus BX60) and images were captured with a digital camera (Olympus DP50). The specificity of immunostaining was tested using primary antisera pre-absorbed with excess amount of homologus antigen (100µg of peptide per ml antiserum in working dilution). (Fig. 1) . Vildagliptin did not affect body weight during the study period. Fig. 2; Table 1 ). After five weeks of treatment, an intravenous glucose tolerance test was undertaken. The insulin response to intravenous glucose was significantly lower in transgenic mice than in wildtype mice (P<0.001) along with a trend of glucose intolerance in transgenic mice (P=0.08). Vildagliptin markedly increased the insulin response to intravenous glucose (P=0.006) and improved the glucose tolerance in hIAPP transgenic mice (P=0.018). Fig. 3 ; Table 1 versus wildtype animals (n=6). In vildagliptin transgenic animals, baseline GLP-1 levels were slightly higher (2.2±0.3 pmol/l; n=7) than in transgenic controls (1.5±0.7 pmol/l; n=6) although the difference did not reach significance (P=0.09). Following the gastric glucose administration, the increase in the GLP-1 levels was markedly augmented in vildagliptin treated animals (Fig. 4) . Thus, after 15 min, GLP-1 levels were 2.4±0.7 pmol/l in transgenic controls versus 11.8±3.2 pmol/l in vildagliptin treated animals (P=0.011). The 60 min AUC for GLP-1 levels was 41±19 pmol/l x min in transgenic controls (and 38.0±9 pmol/l x min in wildtype controls) and this was increased to 225±86 pmol/l x min by vildagliptin in transgenic animals (P<0.008). (Fig. 5) . After nine weeks of treatment with vildagliptin, islets were isolated and incubated for 60 min in the presence of different concentrations of glucose.
Calculations
Results
Body weight and basal glucose and insulin
Intravenous glucose tolerance test (
Gastric glucose tolerance test (
Islet studies in vitro
Transgenic mice had markedly impaired glucose-stimulated insulin secretion (P<0.001). The insulin secretion in response to glucose was augmented in islets isolated from vildagliptintreated mice. (P=0.006 at 16.7 mmol/l and P<0.001 at 22.2 mmol/l) After nine weeks of treatment, also the islet content of insulin was determined (n=18 observations; each with four islets in each group). It was found that transgenic mice had a reduced pancreatic insulin content compared to wildtype mice (4.2±0.4 pmol/islet versus 6.3±0.6 pmol/islet; P<0.001). Following the nine weeks treatment of transgenic mice with vildagliptin, pancreatic insulin content had normalized (6.1±0.6 pmol/islet, P<0.001 vs transgenic controls). (Fig. 6 ). Double immunostaining for insulin and glucagon revealed that hIAPP transgenic islets displayed disturbed intra-islet topography, with centrally located a-cells frequently occurring (Fig 6 B) , compared to wild type islets (Fig 6A) , as expected (19) .
Immunocytochemistry
Treatment with vildagliptin restored the islet topography (Fig 6C) . In addition, hIAPP transgenic mice displayed generally weaker and marked cell-to-cell variation in insulin immunostaining compared to wild type. Treatment with vildagliptin restored the insulin immunostaining pattern.
Discussion
Vildagliptin is an orally active and highly selective inhibitor of DPP-4 (20) that exerts antidiabetic activity in type 2 diabetes and therefore is explored as a new treatment for this disease (8, 9) . Previously we have shown that vildagliptin (also called LAF-237) improves glucose tolerance in high-fat fed glucose intolerant mice (25) . Vildagliptin also has been shown to augment the insulin response to oral glucose and glucose tolerance in obese Zucker rats (20) and to improve glucose tolerance in ob/ob mice (26) and Zucker diabetic fatty rats (27) . The antidiabetic action of vildagliptin relies on increased concentrations of active (intact) GLP-1, since DPP-4 inhibition prevents the inactivation of the incretin hormone (1-3).
These findings suggest that improvement of islet function is the main mechanism underlying the antidiabetic action of DPP-4 inhibition. Therefore, if islet function is severely suppressed, DPP-4 inhibition may have less effect. This was previously inferred from a study in mice with diabetes due to overexpression of a ß-cell targeted dominant-negative mutant form of HNF-1α, which is a model of monogenic type 2 diabetes (28). In this model, vildagliptin was unable to improve the severe islet dysfunction and restore the glucose intolerance (11) . Hence, DPP-4 inhibition is not able to overcome a dominant dysfunction of the ß cell glucose sensing apparatus in rodents.
In this study, we explored the effects vildagliptin in the mouse model of targeted β-cell overexpression of human IAPP, which is associated with impaired insulin secretion and glucose intolerance (12) . We found that in this model, vildagliptin improves glucose tolerance and the insulin response to gastric glucose in mice with transgenic overexpression of hIAPP. In several animal models of type 2diabetes, IAPP is overexpressed (29, 30) . This suggests that IAPP may contribute to diabetes development, in view of the ability of the peptide to inhibit insulin secretion (14) (15) (16) and to form fibrils, which may be toxic to islet β-cells (17) . Hence, our re-sults show that overexpression of IAPP does not compromise the action of DPP-4 inhibition, which further emphasizes the potential of this strategy for treatment of type 2 diabetes.
In this study, we also determined the plasma levels of active GLP-1 after gastric glucose administration. We found that gastric glucose in transgenic controls increased active GLP-1 to the same extent as in wildtype controls. This increase in GLP-1 after gastric glucose was markedly augmented by vildagliptin; the 60 min AUC for GLP-1 levels was increased fivefold by vildagliptin. This illustrates that vildagliptin inhibits DPP-4 markedly in mice and also the rapid inactivation of the incretin which is instituted by DPP-4. Our present finding verifies previous studies of increased GLP-1 levels after vildagliptin administration in humans (9) . Of potential interest is also the finding that following the nine week treatment, vildagliptin tended to increase the fasting plasma GLP-1 levels, i.e., not only GLP-1 levels after but also before the glucose load was administered. Since this difference, however, did not reach significance in this experiment, the finding needs further investigation. If verified, this pattern is similar to that in a previous study in humans demonstrating increased fasting GLP-1 levels by vildagliptin (31) . This suggests a long-term action on the dynamics of GLP-1 by DPP-4 inhibition.
Our results also showed that vildagliptin improved insulin secretion after intravenous glucose, and glucose-stimulated insulin secretion from isolated islets. Furthermore, also islet insulin content was increased by vildagliptin; in fact, the islet insulin content was normalized by vildagliptin in the transgenic mice. This shows that vildagliptin improves β cell function by both stimulating insulin expression and secretion, which is similar to the long-term ß-cell effects induced by GLP-1 (32, 33) . The hIAPP transgenic mice have a disrupted islet cytoarchitecture, which is seen already early postnatally in mice (19) . The disturbed architecture is character-ß cells alone. Here we show that functional normalisation of the islets upon vildagliptin treatment is accompanied by a normalisation also of the islet cytoarchitecture.
In conclusion, we show that DPP-4 inhibition increases active GLP-1 levels and improves glucose tolerance and islet function with improved islet topography in mice with a ß-cell specific overexpression of human IAPP. These findings support the potential value of DPP-4 inhibition in the treatment of diabetes with the potential of normalising islet function. 
